Biopharma Laboratory Services — Operating Income
Labcorp Holdings Biopharma Laboratory Services — Operating Income decreased by 11.3% to $120.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.9%, from $106.90M to $120.70M. Over 3 years (FY 2022 to FY 2025), Biopharma Laboratory Services — Operating Income shows an upward trend with a 8.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher values indicate stronger operational efficiency and pricing power within the biopharma services market.
Detailed definition
This metric measures the profitability of the Biopharma Laboratory Services segment by subtracting all direct and indire...
Peer comparison
Comparable to 'Segment Operating Profit' reported by major competitors in the clinical trial and biopharma support services industry.
lh_segment_biopharma_laboratory_services_operating_incomeHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $97.28M | $97.28M | $97.28M | $97.28M | $99.08M | $99.08M | $99.08M | $99.08M | $99.90M | $107.40M | $120.90M | $130.70M | $106.90M | $123.30M | $132.20M | $136.10M | $120.70M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +1.9% | +0.0% | +0.0% | +0.0% | +0.8% | +7.5% | +12.6% | +8.1% | -18.2% | +15.3% | +7.2% | +3.0% | -11.3% |
| YoY Change | — | — | — | — | +1.9% | +1.9% | +1.9% | +1.9% | +0.8% | +8.4% | +22.0% | +31.9% | +7.0% | +14.8% | +9.3% | +4.1% | +12.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's biopharma laboratory services — operating income?
- Labcorp Holdings (LH) reported biopharma laboratory services — operating income of $120.70M in Q1 2026.
- How has Labcorp Holdings's biopharma laboratory services — operating income changed year-over-year?
- Labcorp Holdings's biopharma laboratory services — operating income increased by 12.9% year-over-year, from $106.90M to $120.70M.
- What is the long-term trend for Labcorp Holdings's biopharma laboratory services — operating income?
- Over 3 years (2022 to 2025), Labcorp Holdings's biopharma laboratory services — operating income has grown at a 8.6% compound annual growth rate (CAGR), from $389.10M to $498.50M.
- What does biopharma laboratory services — operating income mean?
- The profit generated by the Biopharma Laboratory Services segment after accounting for all operating costs.